VOR Biopharma's valuation surged with telitacicept, yet dilution risks and share structure uncertainty maintain volatility.

Clinical trial timelines for key lymphoma and autoimmune disease programs were delayed by approximately two quarters. Cash and investments totaled $302.6 million at the end of Q2 2025, expected to ...

GAAP revenue was $2.7 million for Q2 2025, missing analyst estimates by 20.6%. Operating expenses surged, driven by costs tied to the ACELYRIN merger and clinical trial acceleration. The merger ...

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell ...

Vor Bio (VOR) announced on Wednesday that its collaborator, RemeGen Co., achieved the primary goal in a late-stage study in ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

High adherence to the Mediterranean diet is associated with a reduced risk for SLE, with the relationship partially mediated by certain liver and kidney function biomarkers.

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products Administration (NMPA), which has already approved the drug as a treatment for ...

RemeGen announced that it plans to submit a Biologics License Application (BLA) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for primary ...

Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...